The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2017 | Abstracts presented at ASCO 2017: drug re-challenge and pharmacoeconomics
Vamsidhar Velcheti, MD, from the Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, discusses an abstract presented by Dr. Santini from the Memorial Sloane Kettering at ASCO 2017, which was focused on evaluating the effectiveness and safety of re-challenging patients with immunotherapy, namely PD1/PDL1 inhibitors and/or CTLA-4 inhibitors. He also talks about another abstract presented at ASCO, which was a pharmacoeconomic study evaluating the cost-effectiveness of a flat dose of pembrolizumab in comparison to personalised dosing of the drug. This interview was filmed at the American Society of Oncology (ASCO) 2017 Annual Meeting in Chicago, IL.
